Cadex Genomics develops molecular diagnostic tests to guide cancer treatment using liquid-based technology to provide personalized insight into the therapy response. By combining proven approaches to measuring DNA with cutting-edge technology to improve accuracy and sensitivity Cadex Genomics provides unique insight into therapy response using simple blood draws. Alibrex is a blood-based assay, developed to help physicians identify patients who are not responding to drug therapy. The test is optimized to maximize NPV, that is, minimize the number of false non-responders.